Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04638452
Recruiting Not applicable

Evaluation of Behavioural Psycho & Physiological Responses in People With ASD During a Blood Test in Routine Care Practice

NCT04638452 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-02-08
Last updated
2026-03-16

Condition(s) studied

Autism Spectrum Disorder

Investigational drug(s) / intervention(s)

Video & movements recordingQuestionnaires

Video & movements recording: Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test

Questionnaires: Passing self and hetero questionnaires of emotion felt and perceived.

Study summary

The project is a prospective study designed to characterize behaviour and its psycho-physiological correlates of participants with ASD (children and adults) in comparison with subjects without ASD matched in age during blood test in common practice.

Eligibility

Sex
ALL
Min age
6 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: All participants : * Person over 6 years of age * Person who consent to participate in the study * Membership of the social security scheme * Person who not received analgesic treatment that may interfere with pain perception * Person with medical prescription for blood sample Participants with ASD : * Person with ASD diagnosis * If applicable, legal authority consent to participate in the study Exclusion Criteria: All participants : * Person with unstabilized drug therapy * Person with acute or chronic pain * Person with pathology or receiving a treatment which can have an impact in modification of the pain * Person with oculomotor and/or neuro-motor disorders * Pregnant or breastfeeding woman * Person with deprivation of liberty * Person who no consent to participate in the study or no consent to realised video recording Participants without ASD : * Protected adult * Person with ASD diagnosis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Charles PERRENS Bordeaux France Recruiting

More Centre Hospitalier Charles Perrens, Bordeaux trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04638452 on ClinicalTrials.gov ↗ ← All trials in France